RxDoctor Payments Data

Dat Nguyen, MD

Family Medicine · la Mesa, CANPI 1386626448

Payments from drug & device makers

$490in general payments, 2019–2025

Across 6 payments — averaging $81.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$243
  • Biosense Webster, Inc.$125
  • Lilly USA, LLC$86
  • Pfizer$18
  • AbbVie$18

What the payments were for

  • Food & beverage$490100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$490 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$270,128
Medicare patients
224
Services billed
2,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$89,391
EliquisApixaban94$28,026
CreonLipase/Protease/Amylase17$9,914
Clonidine47$6,224
Midodrine Hcl38$5,338
Sevelamer Carbonate21$4,690
JanuviaSitagliptin Phosphate17$4,318
JardianceEmpagliflozin15$3,735
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$3,160
Tacrolimus20$3,100
Divalproex Sodium46$3,040
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,079
Atorvastatin Calcium121$1,740
Bupropion XlBupropion Hcl23$1,731
Pantoprazole Sodium67$1,671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$28,02694 claims
AbbVieCreon$18$9,91417 claims
Lilly USA, LLCOlanzapine$86$1,60379 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →